O. Dassonville, J. L. Formento, M. Francoual, A. Ramaioli, J. Santini et al., Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer, J. Clin. Oncol, vol.11, pp.1873-1878, 1993.

R. Grandis, J. Melhem, M. F. Barnes, E. L. Tweardy, and D. J. , Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck, Cancer, vol.78, pp.1284-1292, 1996.

J. R. Grandis, M. F. Melhem, W. E. Gooding, R. Day, V. A. Holst et al., Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival, J. Natl. Cancer Inst, vol.90, pp.824-832, 1998.

J. Santini, J. Formento, M. Francoual, G. Milano, M. Schneider et al., Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas, Head Neck, vol.13, pp.132-139, 1991.

A. G. Sacco and F. P. Worden, Molecularly targeted therapy for the treatment of head and neck cancer: A review of the ErbB family inhibitors, OncoTargets Ther, vol.9, pp.1927-1943, 2016.

J. A. Bonner, P. M. Harari, J. Giralt, N. Azarnia, D. M. Shin et al., Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med, vol.354, pp.567-578, 2006.

L. F. Chen, E. E. Cohen, and J. Grandis, New strategies in head and neck cancer: Understanding resistance to epidermal growth factor receptor inhibitors, Clin. Cancer Res, vol.16, pp.2489-2495, 2010.

C. Boeckx, M. Baay, A. Wouters, P. Specenier, J. B. Vermorken et al., Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance, Oncologist, vol.18, pp.850-864, 2013.

P. Vaupel, Blood Flow and Oxygenation Status of Head and Neck Carcinomas, Adv. Exp. Med. Biol, vol.428, pp.89-95, 1997.

D. M. Aebersold, P. Burri, K. T. Beer, J. Laissue, V. Djonov et al., Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer, Cancer Res, vol.61, pp.2911-2916, 2001.

N. J. Beasley, R. Leek, M. Alam, H. Turley, G. J. Cox et al., Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients, Cancer Res, vol.62, pp.2493-2497, 2002.

M. Ströfer, W. Jelkmann, E. Metzen, U. Brockmeier, J. Dunst et al., Stabilisation and Knockdown of HIF-Two Distinct Ways Comparably Important in Radiotherapy, Cell. Physiol. Biochem, vol.28, pp.805-812, 2011.

R. J. Phillips, J. Mestas, M. Gharaee-kermani, M. D. Burdick, A. Sica et al., Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha, J. Biol. Chem, vol.280, pp.22473-22481, 2005.

M. Y. Koh, R. Lemos, . Jr, X. Liu, and G. Powis, The hypoxia-associated factor switches cells from HIF-1alpha-to HIF-2alpha-dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion, Cancer Res, vol.71, pp.4015-4027, 2011.

U. Lendahl, K. L. Lee, H. Yang, and L. Poellinger, Generating specificity and diversity in the transcriptional response to hypoxia, Nat. Rev. Genet, vol.10, pp.821-832, 2009.

J. A. Bertout, S. A. Patel, and M. C. Simon, The impact of O2 availability on human cancer, Nat. Rev. Cancer, vol.8, pp.967-975, 2008.

J. Kim and J. Lee, Targeting Tumor Adaption to Chronic Hypoxia: Implications for Drug Resistance, and How It Can Be Overcome, Int. J. Mol. Sci, vol.18, p.1854, 2017.

D. Verduzco, M. Lloyd, L. Xu, A. Ibrahim-hashim, Y. Balagurunathan et al., Intermittent Hypoxia Selects for Genotypes and Phenotypes That Increase Survival, Invasion, and Therapy Resistance, PLoS ONE, vol.10, 2015.

A. Wouters, B. Pauwels, F. Lardon, and J. B. Vermorken, Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions, Oncologist, vol.12, pp.690-712, 2007.

A. S. Wozny, A. Lauret, P. Battiston-montagne, J. B. Guy, M. Beuve et al., Differential pattern of HIF-1alpha expression in HNSCC cancer stem cells after carbon ion or photon irradiation: One molecular explanation of the oxygen effect, Br. J. Cancer, vol.116, pp.1340-1349, 2017.

P. Bossi, C. Resteghini, N. Paielli, L. Licitra, S. Pilotti et al., Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma, Oncotarget, vol.7, pp.74362-74379, 2016.

X. Yang, H. Zhu, Y. Ge, J. Liu, J. Cai et al., Melittin enhances radiosensitivity of hypoxic head and neck squamous cell carcinoma by suppressing HIF-1alpha, Tumour Biol, vol.35, pp.10443-10448, 2014.

O. Ekshyyan, Y. Rong, X. Rong, K. M. Pattani, F. Abreo et al., Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma, Mol. Cancer Ther, vol.8, pp.2255-2265, 2009.

A. Cassell, M. L. Freilino, J. Lee, S. Barr, L. Wang et al., Targeting TORC1/2 Enhances Sensitivity to EGFR Inhibitors in Head and Neck Cancer Preclinical Models, Neoplasia, vol.14, pp.1005-1014, 2012.

Z. Wang, D. Martin, A. A. Molinolo, V. Patel, R. Iglesias-bartolome et al., mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations, J. Natl. Cancer Inst, vol.106, 2014.

F. S. Subtil, J. Wilhelm, V. Bill, N. Westholt, S. Rudolph et al., Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency, FASEB J, vol.28, pp.1412-1421, 2014.

H. Lu, K. Liang, Y. Lu, and Z. Fan, The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1alpha, Cancer Lett, vol.322, pp.78-85, 2012.

M. Y. Koh and G. Powis, Passing the baton: The HIF switch, Trends Biochem. Sci, vol.37, pp.364-372, 2012.

R. Cabanillas, J. P. Rodrigo, P. Secades, A. Astudillo, C. S. Nieto et al., The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer, Cancer, vol.107, pp.757-766, 2006.

M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, C. Simopoulos, H. Turley et al., Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer, Int. J. Radiat. Oncol, vol.53, pp.1192-1202, 2002.

Q. Zhen, J. Liu, J. Liu, R. Wang, W. Chu et al., Endothelial PAS domain-containing protein 1 confers TKI-resistance by mediating EGFR and MET pathways in non-small cell lung cancer cells, Cancer Boil. Ther, vol.16, pp.549-557, 2015.

C. Méndez-blanco, F. Fondevila, A. García-palomo, J. González-gallego, and J. L. Mauriz, Sorafenib resistance in hepatocarcinoma: Role of hypoxia-inducible factors, Exp. Mol. Med, vol.50, 2018.

D. Zhao, B. Zhai, C. He, G. Tan, X. Jiang et al., Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGF-alpha/EGFR pathway in hepatocellular carcinoma cells, Cell Signal, vol.26, pp.1030-1039, 2014.

M. Prieto-vila, R. Takahashi, W. Usuba, I. Kohama, and T. Ochiya, Drug Resistance Driven by Cancer Stem Cells and Their Niche, Int. J. Mol. Sci, vol.18, 2017.

B. Das, R. Tsuchida, D. Malkin, G. Koren, S. Baruchel et al., Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction, Stem Cells, vol.26, pp.1818-1830, 2008.

C. Zhang, W. I. Zhi, H. Lu, D. Samanta, I. Chen et al., Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217-and ALKBH5-mediated modulation of RNA methylation in breast cancer cells, Oncotarget, vol.7, pp.64527-64542, 2016.

R. Petruzzelli, D. R. Christensen, K. L. Parry, T. Sanchez-elsner, and F. D. Houghton, HIF-2alpha regulates NANOG expression in human embryonic stem cells following hypoxia and reoxygenation through the interaction with an Oct-Sox cis regulatory element, PLoS ONE, vol.9, 2014.

Y. Yan, F. Liu, L. Han, L. Zhao, J. Chen et al., HIF-2alpha promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways, J. Exp. Clin. Cancer Res, vol.37, 2018.

R. R. Weichselbaum, W. Dahlberg, M. Beckett, T. Karrison, D. Miller et al., Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head-and neck-cancer patients, Proc. Natl. Acad. Sci, vol.83, pp.2684-2688, 1986.

J. Gioanni, M. Samson, E. Zanghellini, C. Mazeau, F. Ettore et al., Characterization of a new surface epitope specific for human epithelial cells defined by a monoclonal antibody and application to tumor diagnosis, Cancer Res, vol.47, pp.4417-4424, 1987.

H. Ballo, P. Koldovsky, T. Hoffmann, V. Balz, B. Hildebrandt et al., Establishment and characterization of four cell lines derived from human head and neck squamous cell carcinomas for an autologous tumor-fibroblast in vitro model, Anticancer Res, vol.19, pp.3827-3836, 1999.

H. Modjtahedi, B. C. Cho, M. C. Michel, and F. Solca, A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer, Naunyn-Schmiedebergs Arch. Pharmacol, vol.387, pp.505-521, 2014.

M. Hamilton, J. L. Wolf, J. Rusk, S. E. Beard, G. M. Clark et al., Effects of Smoking on the Pharmacokinetics of Erlotinib, Clin. Cancer Res, vol.12, pp.2166-2171, 2006.

S. Job, A. De-reyniès, B. Heller, A. Weiss, E. Guérin et al., Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction, Cancers, vol.11, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02363219

K. M. Quesnelle, S. E. Wheeler, M. K. Ratay, and J. R. Grandis, Preclinical modeling of EGFR inhibitor resistance in head and neck cancer, Cancer Boil. Ther, vol.13, pp.935-945, 2012.

A. B. Nair and S. Jacob, A simple practice guide for dose conversion between animals and human, J. Basic Clin. Pharm, vol.7, pp.27-31, 2016.

, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, © 2019 by the authors. Licensee MDPI